ClinicalTrials.gg
Active, not recruitingNCT06237335Updated Aug 19, 2026

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

A Phase 2 interventional study of RCT2100 and Placebo in Cystic Fibrosis, sponsored by ReCode Therapeutics. Active, not recruiting at 23 sites in 5 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by ReCode Therapeutics · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
101st of 517
128 · median 36
Started
2024
with 29 others
Phase 2
103 of 717
10 open now
Primary completion
2026-11
later than 25 of 108 live
Registered
655th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 101st largest by enrollment of the 517 interventional ones that give a count, is one of 30 that started in 2024, is one of 103 in phase 2, reaches primary completion later than 25 of the 108 other live ones, and was the 655th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

Read the detailed description

This is a multi-part study to assess the safety, tolerability, and biodistribution of a single ascending dose of inhaled RCT2100 administered via nebulizer to healthy participants (Part 1), the safety and tolerability of multiple-ascending doses of inhaled RCT2100 administered to participants with CF (Part 2), and the safety and tolerability of RCT2100 co-administered with ivacaftor in participants with CF (Part 3).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • Cystic Fibrosis
  • CF
  • mRNA
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part 1 Major Inclusion Criteria:

  • Healthy, adult, male or female, 18-55 years of age, inclusive, at screening.
  • Body weight greater than or equal to 50 kg and (BMI) between 16-32 kg/m2, inclusive
  • The participant has a (FEV1) of at least 80% predicted
  • The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead results, and physical examination findings at screening.
  • Understands the study procedures in the form (ICF), and is willing and able to comply with the protocol.

Part 1 Major Exclusion Criteria:

  • History or presence of medical, surgical, clinical laboratory, or psychiatric condition or disease.
  • The participant has supine blood pressure (BP) >150 mm Hg (systolic) or >90 mm Hg (diastolic), following at least 5 minutes of supine rest.
  • The participant has abnormal clinical laboratory tests at screening, as assessed by the study-specific laboratory.
  • The participant is a smoker or has used nicotine or nicotine-containing products 6 weeks before the first dose of study drug. Former smokers with greater than 10 pack years of smoking history are excluded.

Part 2 Major Inclusion Criteria:

  • Confirmed diagnosis of CF
  • Forced expiratory volume in 1 second ≥50% and ≤100% of predicted mean value for age, sex, and height
  • a) Not eligible for CFTR modulators based on having mutations of CFTR gene on both alleles that are not responsive to CFTR modulator therapy OR
  • b) Eligible for CFTR modulators (based on local prescribing information) but not using CFTR modulators due to intolerance or

Part 2 Major Exclusion Criteria:

  • Hepatic cirrhosis with portal hypertension, moderate hepatic impairment ( Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for sinopulmonary disease within 4 weeks before the first dose of study drug
  • Lung infection with organisms associated with a more rapid decline in pulmonary status
  • Arterial oxygen saturation on room air less than 94% at screening
  • Treatment with a CFTR modulator (Kalydeco, Trikafta, Symdeko, Orkambi, or Alyftrek) within 12 weeks of Screening

Other protocol defined Inclusion/Exclusion criteria may apply.

Part 3 Major Inclusion Criteria:

  • Confirmed diagnosis of CF
  • Forced expiratory volume in 1 second ≥50% and ≤100% of predicted mean value for age, sex, and height
  • a) Not eligible for CFTR modulators based on having mutations of CFTR gene on both alleles that are not responsive to CFTR modulator therapy OR
  • b) Eligible for dual or triple CFTR modulators (based on local prescribing information) but not using CFTR modulators due to intolerance or contraindications

Part 3 Major Exclusion Criteria:

  • Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for sinopulmonary disease within 4 weeks before the first dose of study drug
  • Lung infection with organisms associated with a more rapid decline in pulmonary status
  • Arterial oxygen saturation on room air less than 94% at screening
  • Treatment with a CFTR modulator (Kalydeco, Trikafta, Symdeko, Orkambi, or Alyftrek) within 12 weeks of Screening

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    RCT2100 (Part 1)

    RCT2100 single dose

    Drug: RCT2100

  • Placebo comparator
    Placebo (Part 1)

    Placebo single dose

    Other: Placebo

  • Experimental
    RCT2100 (Part 2) 4 week

    RCT2100 multiple dose

    Drug: RCT2100

  • Experimental
    RCT2100 (Part 2) 12 week

    RCT2100 multiple dose

    Drug: RCT2100

  • Experimental
    Experimental: RCT2100 (Part 3) 6 week

    RCT2100 multiple dose

    Drug: Ivacaftor · Drug: RCT2100

Interventions

  • DrugRCT2100

    RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer

  • OtherPlacebo

    Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer

  • DrugRCT2100

    RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer for 4 weeks

  • DrugRCT2100

    RCT2100 supplied at a single dose strength administered via oral inhalation using nebulizer for 12 weeks

  • ivacaftor administered orally for 6 weeks

  • DrugRCT2100

    RCT2100 supplied at varying dose strengths. Co- administered via oral inhalation using nebulizer for 4 weeks with ivacaftor after initial 2 weeks of ivacaftor dosing run in period

06

What researchers measure

Primary outcomes

  1. Part 1: The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).

    Safety and tolerability as assessed by number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Baseline Through Day 29

  2. Part 2: The number of participants with CF with AEs and SAEs.

    Safety and tolerability of multiple-ascending doses of inhaled RCT2100 administered to participants with CF

    Time frame: From Day 1 through Safety Follow-up, Week 24

  3. Part 3: The number of participants with CF with AEs and SAEs.

    To assess the safety and tolerability of RCT2100 co-administered with ivacaftor in participants with CF.

    Time frame: From Day 1 through Safety Follow-up, Week 24

07

Study locations

23 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Nov 2026, 33 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 33 months is above that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 1, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06237335
Lead sponsor
ReCode Therapeutics
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Feb 1, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Aug 19, 2026

Study contacts

John Matthews, MBBS, MCRP, PhD
study chair · ReCode Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion